Journal of Medicinal Chemistry p. 8811 - 8824 (2018)
Update date:2022-08-05
Topics:
Wang, Junfeng
Wang, Huan
Ramsay, Ian A.
Erstad, Derek J.
Fuchs, Bryan C.
Tanabe, Kenneth K.
Caravan, Peter
Gale, Eric M.
Gd-based MRI contrast agents (GBCAs) have come under intense regulatory scrutiny due to concerns of Gd retention and delayed toxicity. Three GBCAs comprising acyclic Gd chelates, the class of GBCA most prone to Gd release, are no longer marketed in Europe
View MoreBeijing ZhongDaXinHe Chemical Product Co.,Ltd
Contact:010-52876516
Address:tongzhoubeiyuan
Yibin Hope Pharmaceutical Co., Ltd.
Contact:+86-831-5109851 86-831-5109836
Address:Luolong Industrial Zone,Nanxi, Yibin City, Sichuan, China. | Email: wishmarketing@gmail.com | Website: http://www.hopepharma.cc/
Changzhou Chenqiang Chemical Co., Ltd
website:http://www.cq-chem.com
Contact:+86-519-88902455
Address:Shanghuang Town, Liyang City
Shanghai KFSL Pharmaceutical Technology Co.,Ltd.
Contact:+86-21-39971718
Address:859 jiadingchengliu shanghai
Hunan Dinuo Pharmaceutical Co.,Ltd.
Contact:86-731-88280100*8561
Address:Bio-pharmaceutical industrial park, Liuyang, Hunan, China
Doi:10.1021/om960124d
(1996)Doi:10.1021/jm00308a014
(1968)Doi:10.1039/a903340h
(1999)Doi:10.1039/CC9960001253
(1996)Doi:10.1002/jhet.5570330240
(1996)Doi:10.1016/j.tetlet.2005.12.086
(2006)